Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up – Here’s Why

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s share price gapped up prior to trading on Wednesday . The stock had previously closed at $38.95, but opened at $43.66. Zealand Pharma A/S shares last traded at $43.66, with a volume of 175 shares changing hands.

Analysts Set New Price Targets

Several brokerages have commented on ZLDPF. BNP Paribas Exane lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 6th. William Blair reaffirmed a “market perform” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a research report on Thursday, June 4th. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. Three research analysts have rated the stock with a Strong Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy”.

Zealand Pharma A/S Trading Up 12.1%

The firm has a fifty day moving average of $47.94 and a 200-day moving average of $58.85. The company has a debt-to-equity ratio of 0.02, a quick ratio of 37.17 and a current ratio of 37.17. The stock has a market capitalization of $3.12 billion, a price-to-earnings ratio of 3.24 and a beta of 0.86.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.87) EPS for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.50. The company had revenue of $5.33 million for the quarter, compared to analysts’ expectations of $2.81 million. Zealand Pharma A/S had a return on equity of 41.80% and a net margin of 68.82%. As a group, equities analysts predict that Zealand Pharma A/S will post 2.37 earnings per share for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.